CFM
IMRX icon

Catalyst Funds Management’s Immuneering IMRX Stock Holding History

Catalyst Funds Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.5K Buy
+12,800
New +$65.6K 0.01% 521
2024
Q3 		– Sell
-5,600
Closed -$7.17K – 1445
2024
Q2 		$7.17K Buy
+5,600
New +$9.21K ﹤0.01% 994

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Catalyst Funds Management's IMRX Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Immuneering (IMRX) in Q1 2026: 12,800 shares worth $67.5K. The stake represents 0.01% of the portfolio and ranks #521 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in IMRX as recently as Q2 2024.

Catalyst Funds Management first reported a position in IMRX in Q2 2024 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Catalyst Funds Management held 12,800 shares of Immuneering worth $67.5K as of Q1 2026.
  • Immuneering was a new Catalyst Funds Management position in Q1 2026.
  • Immuneering made up 0.01% of Catalyst Funds Management's portfolio in Q1 2026, its #521 holding.
  • Catalyst Funds Management first reported a position in Immuneering in Q2 2024 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.